|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 原发性醛固酮增多症肾上腺静脉采血时醛固酮测量值的变异性显示文摘已有研究描述原发性醛固酮增多症(原醛)患者醛固酮浓度变异性。本研究纳入原醛患者340例,进行回顾性队列研究。受试者在三级转诊中心完成肾上腺静脉采血(adrenal venous sampling,AVS),其中116例在AVS术前数小时测定外周静脉醛固酮水平。AVS由同一介入放射科医生实施,在是否刺激状态下,双侧同时采样,每份样本采3份。主要观察指标包括(1)AVS前和AVS中醛固酮的变化;(2)3份AVS肾上腺静脉醛固酮浓度的变异性。 | Yozamp N Hundemer GL Moussa M Underhill J Fudim T Sacks B Vaidya A 袁源(翻译) 郑武洪(审校) | 2021 | 中华高血压杂志2021，29，11： | 2 |
| 2 | Clinical utility of antihuman lambda chain‐based enzyme‐linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti‐infliximab antibodies显示文摘 | Uri Kopylov Yoav Mazor Miri Yavzori Ella Fudim Lior Katz Daniel Coscas Orit Picard Yehuda Chowers Rami Eliakim Shomron Ben‐Horin | 2011 | Inflamm Bowel Dis2011，，9： | 1 |
| 3 | Racial differences in the prevalence of severe aortic stenosis 显示文摘 | PATEL D K GREEN K D FUDIM M | 2014 | J Am Heart Assoc2014，3，00： | 1 |
| 4 | Carotid body removal for treatment of chronic systolic heart failure显示文摘 | Piotr Niewiński Dariusz Janczak Artur Rucinski Przemyslaw Jazwiec Paul A. Sobotka Zoar J. Engelman Marat Fudim Stanislaw Tubek Ewa A. Jankowska Waldemar Banasiak Emma C.J. Hart Julian F.R. Paton Piotr Ponikowski | 2013 | International Journal of Cardiology2013，，： | 1 |
| 5 | Reversible cardiomyopathies-a review显示文摘 | Huffman C Wagman G Fudim M | 2010 | Transplant Proc2010，42，9： | 1 |
| 6 | Reversible cardiomyopathies-a review显示文摘 | Huffman C Wagman G Fudim M | | 0，，09： | 1 |
| 7 | Revesible cardiomyopathies-a review 显示文摘 | Huffman C Wagman G Fudim M | 2010 | Transplant Proc2010，42，9： | 1 |
| 8 | The carotid body as a therapeut{c target for the treatment of sympathetically mediated diseases显示文摘 | Paton JF Sobotka PA Fudim M | 2013 | Hypertension2013，61，1： | 1 |
| 9 | The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases显示文摘 | Paton JF Sobotka PA Fudim M | 2013 | Hypertension2013，61，12： | 1 |
| 10 | Inflammation in coronary artery disease显示文摘 | CHRISTODOULIDIS G VITTORIO T J FUDIM M | 2014 | Cardiol Rev2014，，： | 1 |
| 11 | Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease显示文摘 | Shomron Ben–Horin Matti Waterman Uri Kopylov Miri Yavzori Orit Picard Ella Fudim Halim Awadie Batia Weiss Yehuda Chowers | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 1 |
| 12 | The neurohor- monal network in the RAAS can bend before breaking 显示文摘 | Wagman G Fudim M Kosmas CE | 2012 | Curt Heart Fail Rep2012，9，2： | 1 |
| 13 | The neurohormonal network in the RAAS can bend before breaking显示文摘 | Wagman G Fudim M Kosmas CE | 2012 | Curr Heart Fail Rep2012，9，2： | 1 |
| 14 | Inflam-mation in coronary artery disease 显示文摘 | Christodoulidis G Vittorio T J Fudim M | 2014 | Cardiol Rev2014，22，6： | 1 |
| 15 | Significance of low level infliximab in the absence of anti-infliximab antibodies显示文摘AIM:To evaluate the prevalence of double negative(DN)sera and the mechanisms responsible for DN status.METHODS:Sera of inflammatory bowel disease patients treated with infliximab(IFX)were tested for drug/antibodies to infliximab(ATI)trough levels and the proportion of DN results was compared between a commercially available double antigen ELISA(with labeled IFX as the detection antibody)and an antilambda ELISA(with anti-human lambda chain detection antibody).Repeat testing with lower than customary serum dilution(1:10)was performed.Patients with DN status were matched with IFX+/ATI-controls and were followed-up for subsequent development of nontransient ATI to investigate if DN status precedes ATI.RESULTS:Of 67 sera obtained at time of loss of response,only 6/67(9%)were DN by anti-lambda ELISA compared to 27/67(40%)with double antigen ELISA(P<0.001,Fisher’s Exact test).Of the latter27 sera,22%were also DN by anti-lambda ELISA,whereas 44%were actually IFX positive(IFX+ATI-),30%were ATI positive(IFX-ATI+)and 4%were double positive(IFX+ATI+).Re-testing using a 1:10 dilution converted most DN results into IFX+and/or ATI+status.Patients with DN status had shorter survival free of non-transient ATI compared with matched controls(log rank test,P<0.001).In 9/30(30%)of these patients,non transient ATI occurred before and after the event at which the DN serum was obtained,supporting the view that a DN result may represent aparticular time-point along the two curves of ATI titer rise and infliximab drug level decline.CONCLUSION:DN status may result from false negative detection of IFX or ATI by double antigen ELISA,suggesting a transitional state of low-level immunogenicity,rather than non-immunological clearance. | Bella Ungar Adi Anafy Henit Yanai Yulia Ron Miri Yavzori Orit Picard Ella Fudim Ronen Loebstein Uri Kopylov Yehuda Chowers Iris Dotan Rami Eliakim Shomron Ben-Horin | 2015 | World Journal of Gastroenterology2015，21，6： | 0 |
| 16 | 形态正常的肾上腺是原发性醛固酮增多症患者醛固酮生成的主要来源显示文摘Am J Hypertens,2022,35(6):561-571.横断面成像显示,正常肾上腺可能是原发性醛固酮增多症(primary aldosteronism,PA)患者醛固酮产生的来源。本文旨在评估形态正常肾上腺中醛固酮生成情况及其对定位研究和治疗决策的影响。方法:研究者对至少1个正常肾上腺的PA患者进行回顾性队列研究,并重新分析当代研究,以评估影像学和肾上腺静脉采血(adrenal venous sampling,AVS)在个体患者和肾上腺水平的解释。 | Parksook WW Yozamp N Hundemer GL Moussa M Underhill J Fudim T Sacks B Vaidya A 刘青 郑武洪 | 2023 | 中华高血压杂志2023，31，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员